Daiichi Sankyo

News

FDA advisors reject one Daiichi Sankyo cancer drug, back ano...

Daiichi Sankyo had a day of mixed fortunes after advisers to the US regulator voted against approval for its leukaemia drug quizartinib, but recommended pexidartinib for a rare tumour.

News

AZ and Daiichi to file new breast cancer drug after trial su...

In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new breast cancer drug – and it looks like the project is on track.

News

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,

News

Lixiana hits the mark in catheter ablation trial

Daiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker hopes new data in atrial fibrillation (AFib) could accelerate its gro

News

Daiichi gets speedy FDA review for rare cancer drug

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT).

News

Daiichi Sankyo takes option on diabetes stem cell start-up

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.

FDA advisors reject one Daiichi Sankyo cancer drug, back ano...

AZ and Daiichi to file new breast cancer drug after trial su...

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

Lixiana hits the mark in catheter ablation trial

Daiichi gets speedy FDA review for rare cancer drug

Daiichi Sankyo takes option on diabetes stem cell start-up

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Daiichi Sankyo

Editor's Picks